Squarepoint
BCRX icon

Squarepoint’s BioCryst Pharmaceuticals BCRX Stock Holding History

Squarepoint’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$379K Sell
39,765
-1,619,427
-98% -$12.6M ﹤0.01% 3533
2025
Q4 		$12.9M Buy
1,659,192
+550,532
+50% +$3.98M 0.01% 963
2025
Q3 		$8.41M Buy
1,108,660
+385,339
+53% +$3.21M 0.01% 1166
2025
Q2 		$6.48M Sell
723,321
-41,577
-5% -$387K 0.01% 1310
2025
Q1 		$5.74M Buy
764,898
+405,017
+113% +$3.27M 0.01% 1339
2024
Q4 		$2.71M Buy
359,881
+345,729
+2,443% +$2.62M ﹤0.01% 2153
2024
Q3 		$108K Buy
+14,152
New +$108K ﹤0.01% 3859
2024
Q2 		– Sell
-97,614
Closed -$496K – 4058
2024
Q1 		$496K Sell
97,614
-223,060
-70% -$1.25M ﹤0.01% 3047
2023
Q4 		$1.92M Sell
320,674
-425,428
-57% -$2.47M ﹤0.01% 2028
2023
Q3 		$5.28M Buy
746,102
+726,378
+3,683% +$5.22M 0.01% 1142
2023
Q2 		$139K Sell
19,724
-131,051
-87% -$1.05M ﹤0.01% 3301
2023
Q1 		$1.26M Sell
150,775
-126,966
-46% -$1.22M 0.01% 1743
2022
Q4 		$3.19M Buy
277,741
+103,574
+59% +$1.29M 0.01% 1086
2022
Q3 		$2.19M Buy
+174,167
New +$2.24M 0.01% 1265
2022
Q2 		– Sell
-303,008
Closed -$4.93M – 2879
2022
Q1 		$4.93M Buy
303,008
+254,642
+526% +$4.08M 0.02% 726
2021
Q4 		$670K Buy
+48,366
New +$640K ﹤0.01% 1952
2021
Q2 		– Sell
-56,770
Closed -$577K – 3222
2021
Q1 		$577K Buy
56,770
+34,615
+156% +$357K ﹤0.01% 1913
2020
Q4 		$165K Buy
22,155
+10,755
+94% +$55.4K ﹤0.01% 2581
2020
Q3 		$39K Sell
11,400
-73,572
-87% -$315K ﹤0.01% 2387
2020
Q2 		$405K Sell
84,972
-2,601
-3% -$10.4K 0.01% 1420
2020
Q1 		$175K Sell
87,573
-531,370
-86% -$1.46M ﹤0.01% 1518
2019
Q4 		$2.13M Buy
618,943
+262,522
+74% +$660K 0.01% 864
2019
Q3 		$1.02M Buy
356,421
+313,308
+727% +$975K 0.01% 1222
2019
Q2 		$163K Sell
43,113
-69,132
-62% -$416K ﹤0.01% 2148
2019
Q1 		$914K Buy
112,245
+65,055
+138% +$557K 0.01% 1151
2018
Q4 		$381K Sell
47,190
-13,421
-22% -$104K ﹤0.01% 1392
2018
Q3 		$462K Sell
60,611
-65,103
-52% -$437K 0.01% 1335
2018
Q2 		$720K Buy
+125,714
New +$692K 0.01% 1025
2017
Q4 		– Sell
-65,389
Closed -$343K – 2082
2017
Q3 		$343K Buy
65,389
+30,390
+87% +$156K 0.01% 1120
2017
Q2 		$195K Buy
34,999
+18,199
+108% +$111K ﹤0.01% 1313
2017
Q1 		$141K Sell
16,800
-18,625
-53% -$130K ﹤0.01% 1356
2016
Q4 		$224K Buy
+35,425
New +$184K 0.01% 1352
2016
Q2 		– Sell
-41,197
Closed -$117K – 1101
2016
Q1 		$117K Buy
41,197
+13,997
+51% +$62K 0.01% 1061
2015
Q4 		$281K Buy
+27,200
New +$270K 0.03% 824

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Squarepoint's BCRX Position: Q1 2026 in Review

Squarepoint reduced its BioCryst Pharmaceuticals (BCRX) stake by 98% in Q1 2026, selling an estimated $12.6M and leaving 39,765 shares worth $379K. The position accounts for ﹤0.01% of the portfolio, ranked #3533.

Squarepoint first reported a position in BCRX in Q4 2015 and has held it in 34 quarters since. The position peaked at $12.9M in Q4 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Squarepoint held 39,765 shares of BioCryst Pharmaceuticals worth $379K as of Q1 2026.
  • Squarepoint sold 1,619,427 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $12.6M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3533 holding.
  • Squarepoint first reported a position in BioCryst Pharmaceuticals in Q4 2015 and has held it in 34 quarters since.
  • Squarepoint's BioCryst Pharmaceuticals position peaked at $12.9M in Q4 2025.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.